Agreed that this was an overall testimonial "hang in there" call but we knew that was likely since no PRs with real news from last week's activities.
A) I may be totally off here but wondering if FDA/MHRA are refusing to grant EUA based on CD10 data because:
1) they see REAL target is CD12 AND
2) CD10 approval could open up floodgates for off-label use FOR CD12? (And, as you pointed out, delays help big pharma as they catch up)
B) HC Wainwright and Ameriprise Financial on call
C) Now up to 21 Employees
D) What, exactly, are they expecting from NASDAQ next week?
E) Gilead's acquisition of Immunogenics for $21B interesting starting point considering Leronlimab potential for so many ailments.
E) MHRA asked for the anectdotal data and CYDY in process of assembling.